Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/33065
Title: Sodium Bicarbonate for Metabolic Acidosis in the ICU: Results of a Pilot Randomized Double-Blind Clinical Trial.
Austin Authors: Serpa Neto, Ary ;Fujii, Tomoko;McNamara, Mairead;Moore, James;Young, Paul J;Peake, Sandra;Bailey, Michael;Hodgson, Carol;Higgins, Alisa M;See, Emily J ;Secombe, Paul;Campbell, Lewis;Young, Meredith;Maeda, Mikihiro;Pilcher, David;Nichol, Alistair;Deane, Adam;Licari, Elisa;White, Kyle;French, Craig;Shehabi, Yahya;Cross, Anthony;Maiden, Matthew;Kadam, Umesh;El Khawas, Khaled;Cooper, Jamie;Bellomo, Rinaldo ;Udy, Andrew
Affiliation: Australian and New Zealand Intensive Care Research Centre (ANZIC-RC), School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia
Intensive Care Unit, The Jikei University School of Medicine, Tokyo, Japan.
Medical Research Institute of New Zealand, Wellington, New Zealand.
Intensive Care Unit, Wellington Hospital, Wellington, New Zealand.
University of Melbourne Clinical School
Department of Intensive Care Medicine, The Queen Elizabeth Hospital, Woodville South, Australia.;Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, Australia.
The Australian and New Zealand Intensive Care Society (ANZICS) Centre for Outcome and Resource Evaluation (CORE), Melbourne, Australia.
College of Medicine and Public Health, Flinders University, Bedford Park, Australia
Intensive Care
Intensive Care Unit Alice Springs Hospital, Alice Springs, Australia
College of Medicine and Public Health, Flinders University, Bedford Park, Australia
Department of Intensive Care and Hyperbaric Medicine, The Alfred Hospital, Melbourne, Australia.
Department of Pharmacy, St. Marianna University School of Medicine Hospital, Kawasaki, Japan.
Faculty of Medicine, University of Queensland, Brisbane, Queensland, Australia.
Intensive Care Unit, Royal Melbourne Hospital, Melbourne, Victoria, Australia.
Department of Intensive Care, Western Health, Melbourne, Victoria, Australia.
Intensive Care Unit, Princess Alexandra Hospital, Woolloongabba, Queensland, Australia
Department of Medicine, Western Health, Melbourne Medical School, The University of Melbourne, Melbourne, Victoria, Australia
Monash University, School of Clinical Sciences, Clayton, Victoria, Australia
Department of Intensive Care Medicine, Northern Health, Epping, Victoria, Australia
Intensive Care Unit, University Hospital Geelong, Barwon Health, Geelong, Victoria, Australia
Department of Intensive Care Medicine, Werribee Mercy Hospital, Werribee, Victoria, Australia
Intensive Care Unit, Grampians Health, Ballarat, Victoria, Australia.
Department of Critical Care Medicine, Hospital Israelita Albert Einstein, São Paulo, Brazil.
Data Analytics Research and Evaluation (DARE) Centre
Centre for Integrated Critical Care, University of Melbourne, Parkville, Victoria, Australia.
Intensive Care, University of New South Wales, Kensington Campus, School of Clinical Medicine, Sydney, New South Wales, Australia.
Intensive Care Unit, Royal Darwin Hospital, Darwin, Australia.
Intensive Care Services, Monash Health, Clayton, Victoria, Australia
Intensive Care Unit, Royal Adelaide Hospital, Adelaide, South Australia, Australia.
Department of Intensive Care Medicine, Monash Health Casey Hospital, Berwick, Victoria, Australia
Department of Intensive Care Medicine, Epworth Hospital Geelong, Waurn Ponds, Victoria, Australia.
Issue Date: 1-Nov-2023
Date: 2023
Publication information: Critical Care Medicine 2023-11-01; 51(11)
Abstract: To identify the best population, design of the intervention, and to assess between-group biochemical separation, in preparation for a future phase III trial. Investigator-initiated, parallel-group, pilot randomized double-blind trial. Eight ICUs in Australia, New Zealand, and Japan, with participants recruited from April 2021 to August 2022. Thirty patients greater than or equal to 18 years, within 48 hours of admission to the ICU, receiving a vasopressor, and with metabolic acidosis (pH < 7.30, base excess [BE] < -4 mEq/L, and Paco2 < 45 mm Hg). Sodium bicarbonate or placebo (5% dextrose). The primary feasibility aim was to assess eligibility, recruitment rate, protocol compliance, and acid-base group separation. The primary clinical outcome was the number of hours alive and free of vasopressors on day 7. The recruitment rate and the enrollment-to-screening ratio were 1.9 patients per month and 0.13 patients, respectively. Time until BE correction (median difference, -45.86 [95% CI, -63.11 to -28.61] hr; p < 0.001) and pH correction (median difference, -10.69 [95% CI, -19.16 to -2.22] hr; p = 0.020) were shorter in the sodium bicarbonate group, and mean bicarbonate levels in the first 24 hours were higher (median difference, 6.50 [95% CI, 4.18 to 8.82] mmol/L; p < 0.001). Seven days after randomization, patients in the sodium bicarbonate and placebo group had a median of 132.2 (85.6-139.1) and 97.1 (69.3-132.4) hours alive and free of vasopressor, respectively (median difference, 35.07 [95% CI, -9.14 to 79.28]; p = 0.131). Recurrence of metabolic acidosis in the first 7 days of follow-up was lower in the sodium bicarbonate group (3 [20.0%] vs. 15 [100.0%]; p < 0.001). No adverse events were reported. The findings confirm the feasibility of a larger phase III sodium bicarbonate trial; eligibility criteria may require modification to facilitate recruitment.
URI: https://ahro.austin.org.au/austinjspui/handle/1/33065
DOI: 10.1097/CCM.0000000000005955
ORCID: 
Journal: Critical Care Medicine
PubMed URL: 37294139
ISSN: 1530-0293
Type: Journal Article
Appears in Collections:Journal articles

Show full item record

Page view(s)

68
checked on Apr 15, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.